AKT1 and breast carcinoma: In trastuzumab-sensitive breast cancer cells, both trastuzumab and pertuzumab block ErbB2 dimerization and inhibit the activation of the main downstream pathways of ErbB2: PI3K/AKT and MAPK/ERK signaling pathways [7, 8, 17].